Bone Anabolic Agents for the Treatment of Multiple Myeloma

Overview

Journal Cancer Microenviron

Publisher Springer

Specialty Oncology

Date 2011 Dec 6

PMID 22139744

Citations 9

Authors

Sonia Vallet

Noopur Raje

Affiliations

Soon will be listed here.

Abstract

The majority of patients with multiple myeloma develop bone osteolytic lesions, which may lead to severe complications, including pain and fractures. The pathogenesis of bone disease depends on uncoupled bone remodeling, characterized by increased bone resorption due to upregulation of osteoclast activity and decreased bone formation due to osteoblast inhibition. In myeloma, impaired osteoblast differentiation and increased apoptosis have been described. Responsible for these effects are integrin-mediated adhesion to tumor cells and soluble factors, including WNT antagonists, BMP2 inhibitors and numerous cytokines. Based on the evidence of osteoblast suppression in myeloma, bone anabolic agents have been developed and are currently undergoing clinical evaluation. Due to bidirectional inhibitory effects characterizing tumor cells and osteoblasts interactions, agents targeting osteoblasts are expected to reduce tumor burden along with improvement of bone health. This review summarizes the current knowledge on osteoblast inhibition in myeloma and provides an overview on the clinical grade agents with bone anabolic properties, which represent new promising therapeutic strategies in myeloma.

Citing Articles

The role of Wnt/β-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma (review).

Yuan Y, Guo M, Gu C, Yang Y Am J Transl Res. 2021; 13(9):9932-9949.

PMID: 34650674 PMC: 8507016.

Multiple Myeloma as a Bone Disease? The Tissue Disruption-Induced Cell Stochasticity (TiDiS) Theory.

Capp J, Bataille R Cancers (Basel). 2020; 12(8).

PMID: 32759688 PMC: 7463431. DOI: 10.3390/cancers12082158.

Adipose, Bone, and Myeloma: Contributions from the Microenvironment.

McDonald M, Fairfield H, Falank C, Reagan M Calcif Tissue Int. 2016; 100(5):433-448.

PMID: 27343063 PMC: 5396178. DOI: 10.1007/s00223-016-0162-2.

Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.

Eda H, Santo L, Wein M, Hu D, Cirstea D, Nemani N J Bone Miner Res. 2016; 31(6):1225-34.

PMID: 26763740 PMC: 5002355. DOI: 10.1002/jbmr.2789.

Role of bone-anabolic agents in the treatment of breast cancer bone metastases.

Suvannasankha A, Chirgwin J Breast Cancer Res. 2015; 16(6):484.

PMID: 25757219 PMC: 4429670. DOI: 10.1186/s13058-014-0484-9.

References

Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M . Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10(5):537-43. DOI: 10.1093/hmg/10.5.537. View

Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S . Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001; 98(13):3527-33. DOI: 10.1182/blood.v98.13.3527. View

Mukherjee S, Raje N, Schoonmaker J, Liu J, Hideshima T, Wein M . Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008; 118(2):491-504. PMC: 2213372. DOI: 10.1172/JCI33102. View

Terpos E, Politou M, Szydlo R, Goldman J, Apperley J, Rahemtulla A . Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol. 2003; 123(1):106-9. DOI: 10.1046/j.1365-2141.2003.04561.x. View

Olfa G, Christophe C, Philippe L, Romain S, Khaled H, Pierre H . RUNX2 regulates the effects of TNFalpha on proliferation and apoptosis in SaOs-2 cells. Bone. 2010; 46(4):901-10. DOI: 10.1016/j.bone.2009.12.027. View

Delforge M, Terpos E, Richardson P, Shpilberg O, Khuageva N, Schlag R . Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol. 2011; 86(5):372-84. DOI: 10.1111/j.1600-0609.2011.01599.x. View

Pennisi A, Ling W, Li X, Khan S, Shaughnessy Jr J, Barlogie B . The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood. 2009; 114(9):1803-12. PMC: 2738568. DOI: 10.1182/blood-2009-01-201954. View

Saad F, Lipton A, Cook R, Chen Y, Smith M, Coleman R . Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007; 110(8):1860-7. DOI: 10.1002/cncr.22991. View

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B . The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349(26):2483-94. DOI: 10.1056/NEJMoa030847. View

10.

Fuller K, Bayley K, Chambers T . Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun. 2000; 268(1):2-7. DOI: 10.1006/bbrc.2000.2075. View

11.

Ehrlich L, Chung H, Ghobrial I, Choi S, Morandi F, Colla S . IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005; 106(4):1407-14. DOI: 10.1182/blood-2005-03-1080. View

12.

Pennisi A, Ling W, Li X, Khan S, Wang Y, Barlogie B . Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One. 2010; 5(12):e15233. PMC: 3004797. DOI: 10.1371/journal.pone.0015233. View

13.

Jourdan M, Tarte K, Legouffe E, BROCHIER J, Rossi J, Klein B . Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw. 1999; 10(1):65-70. PMC: 2025696. View

14.

Pearsall R, Canalis E, Cornwall-Brady M, Underwood K, Haigis B, Ucran J . A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci U S A. 2008; 105(19):7082-7. PMC: 2383948. DOI: 10.1073/pnas.0711263105. View

15.

Mohammad K, Chen C, Balooch G, Stebbins E, McKenna C, Davis H . Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 2009; 4(4):e5275. PMC: 2666804. DOI: 10.1371/journal.pone.0005275. View

16.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

17.

Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K . Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis. 2006; 23(5-6):291-300. DOI: 10.1007/s10585-006-9038-6. View

18.

Yaccoby S, Wezeman M, Zangari M, Walker R, Cottler-Fox M, Gaddy D . Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006; 91(2):192-9. PMC: 1592551. View

19.

Kumar S, Rajkumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F . Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2007; 111(5):2516-20. PMC: 2254544. DOI: 10.1182/blood-2007-10-116129. View

20.

Vincent C, Findlay D, Welldon K, Wijenayaka A, Zheng T, Haynes D . Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res. 2009; 24(8):1434-49. DOI: 10.1359/jbmr.090305. View